A comparison of viable Eμ-myc p53-/- to Eμ-myc Arf-/- cells along the lymphoma (Figure 5) indicates that the viability is higher for the drug-resistant tumors in the middle of the tumor (Section S3) compared to the drug-sensitive tumors, with a corresponding statistically significant increase in cell density (p = 0.024; Student's t-test with α = 0.05). The gene discussed is MYC; the disease is lymphoma.